TY - JOUR
T1 - The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model
AU - Bourne, Nigel
AU - Bernstein, David I.
AU - Ireland, James
AU - Sonderfan, Andrew J.
AU - Profy, Albert T.
AU - Stanberry, Lawrence R.
N1 - Funding Information:
Received 25 November 1998; revised 10 February 1999; electronically published 1 June 1999. Presented in part: 36th annual meeting of the Infectious Diseases Society of America, Denver, 12–15 November 1998 (abstract 659-Sa). Animal studies were approved by the Children’s Hospital Medical Center Animal Care and Use Committee. Financial support: National Institutes of Health (contract AI-65289, grant AI-37-940). Reprints or correspondence: Dr. Nigel Bourne, Division of Infectious Diseases, Children’s Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229 ([email protected]).
PY - 1999
Y1 - 1999
N2 - Vaginal gel formulations containing the naphthalene sulfonate polymer PRO 2000 are being developed as topical microbicides to protect against infection with sexually transmitted disease (STD) pathogens. A mouse model was used to determine whether PRO 2000 could protect against genital herpes in vivo. Animals received a single intravaginal application of 15 μL of a 10% PRO 2000 aqueous solution or a 4.0% or 0.5% PRO 2000 vaginal gel formulation 20 s prior to intravaginal challenge with 4.0 log10 pfu of herpes simplex virus type 2. Treatment with the 4.0% gel provided complete protection against infection; treatment with the 0.5% gel or 10% solution provided 81% and 80% protection, respectively. Furthermore, the 4% gel provided significant protection even when viral challenge was delayed until 60 min after treatment. This is the first report to show that PRO 2000 can protect against infection with an STD pathogen in vivo.
AB - Vaginal gel formulations containing the naphthalene sulfonate polymer PRO 2000 are being developed as topical microbicides to protect against infection with sexually transmitted disease (STD) pathogens. A mouse model was used to determine whether PRO 2000 could protect against genital herpes in vivo. Animals received a single intravaginal application of 15 μL of a 10% PRO 2000 aqueous solution or a 4.0% or 0.5% PRO 2000 vaginal gel formulation 20 s prior to intravaginal challenge with 4.0 log10 pfu of herpes simplex virus type 2. Treatment with the 4.0% gel provided complete protection against infection; treatment with the 0.5% gel or 10% solution provided 81% and 80% protection, respectively. Furthermore, the 4% gel provided significant protection even when viral challenge was delayed until 60 min after treatment. This is the first report to show that PRO 2000 can protect against infection with an STD pathogen in vivo.
UR - http://www.scopus.com/inward/record.url?scp=0033047793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033047793&partnerID=8YFLogxK
U2 - 10.1086/314853
DO - 10.1086/314853
M3 - Article
C2 - 10353881
AN - SCOPUS:0033047793
SN - 0022-1899
VL - 180
SP - 203
EP - 205
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -